Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Recap by typeshit. Full story at Longevity.Technology.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
The retatrutide rival from United Biotechnology led to weight loss of up to 9.8% at 24 weeks in 211 Chinese adults, beating semaglutide's 4.8%, per Cell Metabolism.
In a JAMA Viewpoint, CSPI authors argue a peptide-friendly advisory panel stacked with industry-tied members threatens drug approval integrity.
6:45
Kim Constable gives her take on peptides aimed at women past 40. Her claims are her own, so watch with that in mind.
Loading…